Filtered By:
Source: Thrombosis and Haemostasis
Condition: Atrial Fibrillation

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 186 results found since Jan 2013.

The C-reactive protein gene polymorphism predicts the risk of thromboembolic stroke in atrial fibrillation: a more than 10-year prospective follow-up study.
CONCLUSION: The CRP gene triallelic polymorphism and the CRP level are associated with the risk of incident thromboembolic stroke in patients with AF. This article is protected by copyright. All rights reserved. PMID: 28498565 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 12, 2017 Category: Hematology Authors: Chang SN, Lai LP, Chiang FT, Lin JL, Hwang JJ, Tsai CT Tags: J Thromb Haemost Source Type: research

Stroke Severity in Patients on Non-Vitamin K Antagonist Oral Anticoagulants with a Standard or Insufficient Dose.
CONCLUSION:  Use of warfarin with a therapeutic intensity or standard-dosed NOACs was associated with a relatively mild stroke in the patients with NVAF. PMID: 30453351 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 19, 2018 Category: Hematology Authors: Jung YH, Choi HY, Lee KY, Cheon K, Han SW, Park JH, Cho HJ, Park HJ, Nam HS, Heo JH, Lee HS, Kim YD Tags: Thromb Haemost Source Type: research

Age-dependent anticoagulant therapy for atrial fibrillation patients with intermediate risk of ischemic stroke: A nationwide population-based study.
CONCLUSIONS: Age is an important determinant of ischemic stroke and composite outcome in intermediate-risk AF patients. The benefit of OAC therapy for these AF patients appears to have an age threshold (age ≥ 55 years). PMID: 33307565 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 11, 2020 Category: Hematology Authors: Choi SY, Kim MHH, Lee KM, Cho YR, Park JS, Yun SC, Lip GY Tags: Thromb Haemost Source Type: research

Monitoring of Direct Oral Anticoagulants Plasma Levels for Secondary Stroke Prevention
CONCLUSIONS: Monitoring of DOAC plasma levels could help to identify patients with increased risk for stroke recurrence and should be considered for certain subgroups, including patients with high GFR.PMID:35171533 | DOI:10.1111/jth.15677
Source: Thrombosis and Haemostasis - February 16, 2022 Category: Hematology Authors: Gabriela Siedler Kosmas Macha Svenja Stoll Johannes Plechschmidt Ruihao Wang Stefan T Gerner Erwin Strasser Stefan Schwab Bernd Kallm ünzer Source Type: research

Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation.
In conclusion, there was a substantial amount of inter-patient variability, and often extreme differences in opinion regarding tolerance of bleeding risk in the context of stroke prevention in atrial fibrillation. These findings highlight the importance of considering patient preferences when deciding on SPAF therapy. PMID: 24337399 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 12, 2013 Category: Hematology Authors: Lahaye S, Regpala S, Lacombe S, Sharma M, Gibbens S, Ball D, Francis K Tags: Thromb Haemost Source Type: research

Stroke prevention in atrial fibrillation: An Asian perspective.
Abstract Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. In 2050, it is estimated that there will be 72 million AF patients in Asia, accounting for almost 2.9 million patients suffering from AF-associated stroke. Asian AF patients share similar risk factor profiles as non-Asians, except that more Asians have a history of previous stroke. Clinical challenges are evident in the field of stroke prevention in AF, amongst Asians. Existing stroke and bleeding risk scores have not been well-validated in Asians. Asians are prone to bleeding when treated with warfarin, and the optimal internationa...
Source: Thrombosis and Haemostasis - February 6, 2014 Category: Hematology Authors: Chiang CE, Wang KL, Lip GY Tags: Thromb Haemost Source Type: research

Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making.
Abstract Concepts and our approaches to stroke prevention in atrial fibrillation (AF) have changed markedly over the last decade. There has been an evolution over the approach to stroke and bleeding risk assessment, as well as new treatment options. An increasing awareness of AF has led to calls to improve the detection of and population screening for AF. Stroke and bleeding risk assessment continues to evolve, and the ongoing debate on balance between simplicity and practicality, against precision medicine will continue. In this review article, we provide an overview of past, present and the (likely) future conce...
Source: Thrombosis and Haemostasis - June 9, 2017 Category: Hematology Authors: Lip G, Lip GYH, Freedman B, De Caterina R, Potpara TS Tags: Thromb Haemost Source Type: research

Risk of ischemic stroke in asymptomatic atrial fibrillation incidentally-detected in primary care compared with other clinical presentations
CONCLUSION: Ischemic stroke risk in patients with AA-AF incidentally-detected in primary care is far from benign, and not less than incident AF presenting clinically in general practice or hospital. This provides justification for identification of previously undetected AF, e.g. by opportunistic screening, and subsequent stroke prevention with thromboprophylaxis, to reduce the approximately 10% of ischemic strokes related to unrecognized AF.PMID:34192776 | DOI:10.1055/a-1541-3885
Source: Thrombosis and Haemostasis - June 30, 2021 Category: Hematology Authors: Christopher Wallenhorst Carlos Martinez Ben Freedman Source Type: research

2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary
Thromb Haemost. 2021 Nov 13. doi: 10.1055/s-0041-1739411. Online ahead of print.ABSTRACTThe consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for cardiologists, neurologists, geriatricians, and general practitioners in the Asia-Pacific region. In these years, many important new data regarding stroke prevention in AF were reported. The practice guidelines subcommittee members comprehensively reviewed updated information on stroke prevention in AF, and summarized them in this 2021 focused update of the...
Source: Thrombosis and Haemostasis - November 13, 2021 Category: Hematology Authors: Tze-Fan Chao Boyoung Joung Yoshihide Takahashi Toon Wei Lim Eue-Keun Choi Yi-Hsin Chan Yutao Guo Charn Sriratanasathavorn Seil Oh Ken Okumura Gregory Y H Lip Source Type: research

Managing uncertainty: Physicians' decision-making for stroke prevention for patients with atrial fibrillation and intracerebral haemorrhage
Conclusion Physicians described the process of deciding on stroke prevention in patients with AF post-ICH as 'challenging' due to considerable 'clinical equipoise'. Key factors that affected decision-making was patient comorbidities, functional status, and patient willingness to engage with oral anticoagulation therapy. Shared decision-making was believed to be beneficial, but physicians believed that the ultimate responsibility to decide on stroke prevention lay with the clinician.PMID:35253141 | DOI:10.1055/a-1789-4824
Source: Thrombosis and Haemostasis - March 7, 2022 Category: Hematology Authors: Elena Ivany Robyn Lotto Gregory Yh Lip Deirdre Lane Source Type: research

Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants.
Abstract This review article discusses the following, as yet unanswered, questions and research priorities to optimise patient management and stroke prevention in atrial fibrillation with the new direct oral anticoagulants (NOACs): 1. In patients prescribed a NOAC, can the anticoagulant effects or plasma concentrations of the NOACs be measured rapidly and reliably and, if so, can "cut-off points" between which anticoagulation is therapeutic (i.e. the "therapeutic range") be defined? 2. In patients who are taking a NOAC and bleeding (e.g. intracerebral haemorrhage), can the anticoagulant effects of the direct NOACs...
Source: Thrombosis and Haemostasis - November 28, 2013 Category: Hematology Authors: Hankey GJ Tags: Thromb Haemost Source Type: research